UNLABELLED: Globally, hepatocellular carcinoma (HCC) accounts for 70%-85% of primary liver cancers and ranks as the second leading cause of male cancer death. Serum alpha-fetoprotein (AFP), normally highly expressed in the liver only during fetal development, is reactivated in 60% of HCC tumors and associated with poor patient outcome. We hypothesize that AFP+ and AFP- tumors differ biologically. Multivariable analysis in 237 HCC cases demonstrates that AFP level predicts poor survival independent of tumor stage (P<0.043). Using microarray-based global microRNA (miRNA) profiling, we found that miRNA-29 (miR-29) family members were the most significantly (P<0.001) down-regulated miRNAs in AFP+ tumors. Consistent with miR-29's role in targeting DNA methyltransferase 3A (DNMT3A), a key enzyme regulating DNA methylation, we found a significant inverse correlation (P<0.001) between miR-29 and DNMT3A gene expression, suggesting that they might be functionally antagonistic. Moreover, global DNA methylation profiling reveals that AFP+ and AFP- HCC tumors have distinct global DNA methylation patterns and that increased DNA methylation is associated with AFP+ HCC. Experimentally, we found that AFP expression in AFP- HCC cells induces cell proliferation, migration, and invasion. Overexpression of AFP, or conditioned media from AFP+ cells, inhibits miR-29a expression and induces DNMT3A expression in AFP- HCC cells. AFP also inhibited transcription of the miR-29a/b-1 locus, and this effect is mediated through c-MYC binding to the transcript of miR-29a/b-1. Furthermore, AFP expression promotes tumor growth of AFP- HCC cells in nude mice. CONCLUSION: Tumor biology differs considerably between AFP+ HCC and AFP- HCC; AFP is a functional antagonist of miR-29, which may contribute to global epigenetic alterations and poor prognosis in HCC.
UNLABELLED: Globally, hepatocellular carcinoma (HCC) accounts for 70%-85% of primary liver cancers and ranks as the second leading cause of male cancer death. Serum alpha-fetoprotein (AFP), normally highly expressed in the liver only during fetal development, is reactivated in 60% of HCC tumors and associated with poor patient outcome. We hypothesize that AFP+ and AFP- tumors differ biologically. Multivariable analysis in 237 HCC cases demonstrates that AFP level predicts poor survival independent of tumor stage (P<0.043). Using microarray-based global microRNA (miRNA) profiling, we found that miRNA-29 (miR-29) family members were the most significantly (P<0.001) down-regulated miRNAs in AFP+ tumors. Consistent with miR-29's role in targeting DNA methyltransferase 3A (DNMT3A), a key enzyme regulating DNA methylation, we found a significant inverse correlation (P<0.001) between miR-29 and DNMT3A gene expression, suggesting that they might be functionally antagonistic. Moreover, global DNA methylation profiling reveals that AFP+ and AFP- HCC tumors have distinct global DNA methylation patterns and that increased DNA methylation is associated with AFP+ HCC. Experimentally, we found that AFP expression in AFP- HCC cells induces cell proliferation, migration, and invasion. Overexpression of AFP, or conditioned media from AFP+ cells, inhibits miR-29a expression and induces DNMT3A expression in AFP- HCC cells. AFP also inhibited transcription of the miR-29a/b-1 locus, and this effect is mediated through c-MYC binding to the transcript of miR-29a/b-1. Furthermore, AFP expression promotes tumor growth of AFP- HCC cells in nude mice. CONCLUSION:Tumor biology differs considerably between AFP+ HCC and AFP- HCC; AFP is a functional antagonist of miR-29, which may contribute to global epigenetic alterations and poor prognosis in HCC.
Authors: C Balsano; M L Avantaggiati; G Natoli; E De Marzio; H Will; M Perricaudet; M Levrero Journal: Biochem Biophys Res Commun Date: 1991-05-15 Impact factor: 3.575
Authors: Tsung-Cheng Chang; Duonan Yu; Yun-Sil Lee; Erik A Wentzel; Dan E Arking; Kristin M West; Chi V Dang; Andrei Thomas-Tikhonenko; Joshua T Mendell Journal: Nat Genet Date: 2007-12-09 Impact factor: 38.330
Authors: C Pistore; E Giannoni; T Colangelo; F Rizzo; E Magnani; L Muccillo; G Giurato; M Mancini; S Rizzo; M Riccardi; N Sahnane; V Del Vescovo; K Kishore; M Mandruzzato; F Macchi; M Pelizzola; M A Denti; D Furlan; A Weisz; V Colantuoni; P Chiarugi; I M Bonapace Journal: Oncogene Date: 2017-06-05 Impact factor: 9.867
Authors: Andrew Gabrielson; Yunan Wu; Hongkun Wang; Jiji Jiang; Bhaskar Kallakury; Zoran Gatalica; Sandeep Reddy; David Kleiner; Thomas Fishbein; Lynt Johnson; Eddie Island; Rohit Satoskar; Filip Banovac; Reena Jha; Jaydeep Kachhela; Perry Feng; Tiger Zhang; Anteneh Tesfaye; Petra Prins; Christopher Loffredo; John Marshall; Louis Weiner; Michael Atkins; Aiwu Ruth He Journal: Cancer Immunol Res Date: 2016-03-11 Impact factor: 11.151
Authors: Mona M Hassouna; Mary Naguib; Enas M Radwan; Mohamed Abdel-Samiee; Suzanne Estaphan; Eman Abdelsameea Journal: Asian Pac J Cancer Prev Date: 2020-11-01